Abstracts tagged "methotrexate (MTX)"

Abstract Number: 1759 • 2019 ACR/ARP Annual Meeting
Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial
stéphanie Ferrero ¹, Ruth Wittoek ², Edem Allado ³, Coralie Cruzel ⁴, Véronique Breuil ¹, Liana Euller Ziegler ⁵, Damien louille ⁶, Christian Roux⁷ and Joel Kremer ⁸, ¹University of Nice, nice, France, ²Ghent University Hospital, Gent University, Gent, Belgium, ³Centre Hospitalier Universitaire de Nancy, Nancy, France, ⁴Université Cote d'Azur, nice, France, ⁵PUPH CHU NICE, nice, France, ⁶Université Cote d'Azur, Nancy, France, ⁷Université Cote d'Azur, Nice, ⁸Albany Medical College, Albany, NY
Background/Purpose: No studies have assessed the effect of methotrexate (MTX) in osteoarthritis of the hand (HOA). The purpose of our study was to examine the…
Abstract Number: 1890 • 2019 ACR/ARP Annual Meeting
Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)
Daniel Solomon¹, Robert Glynn ², Elizabeth Karlson ³, Fengxin Lu ³, Cassandra Corrigan ³, Joshua Colls ³, Chang Xu ³, Jean MacFadyen ³, Medha Barbhaiya ⁴, Nancy Berliner ³, Paul Dellaripa ³, Brendan Everett ³, Sara Hammond ³, Meredith Murray ³, Deepak Rao ³, Susan Ritter ⁵, Anna Rutherford ⁵, Jeffrey Sparks ³, Jacklyn Stratton ⁵, Dong Suh ³, Sara K. Tedeschi ⁶, Kathleen Vanni ³, Nina Paynter ⁵ and Paul Ridker ⁵, ¹Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Harvard Medical School - Boston, MA, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Brigham and Women's Hospital, Boston, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Prior observational studies have estimated the risk of adverse events with low dose methotrexate (MTX). However, prior randomized controlled trials (RCT) were too small…
Abstract Number: 1909 • 2019 ACR/ARP Annual Meeting
miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients
Rohan Machhar¹, Justine (Yang) Ye ², Remy Pollock ¹ and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. Links between altered miRNA expression with the pathogenesis of several autoimmune disorders…
Abstract Number: 2067 • 2019 ACR/ARP Annual Meeting
Comparison of Medication New User Definitions in Multi-Specialty EMR Data
Jeffrey Curtis¹, Lang Chen ¹, Narender Annapureddy ², Cassie Clinton ¹, Megan Clowse ³, Millie Long ⁴, W. Benjamin Nowell ⁵, Jim Oates ⁶, Rennie Rhee ⁷, Siddarth Singh ⁸, Fenglong Xie ⁹ and Timothy Beukelman ¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²Vanderbilt University, Nashville, TN, ³Duke University, Durham, ⁴University of North Carolina Chapel Hill, Chapel Hill, NC, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC, ⁷University of Pennsylvania, Division of Rheumatology, Philadelphia, PA, ⁸University California, San Diego, San Diego, ⁹University of Alabama at Birmingham, Birmingham, ¹⁰University of Alabama Birmingham, Birmingham, AL
Background/Purpose: New user designs are typically preferred in pharmacoepidemiology to avoid bias. The optimal implementation of a new user design in electronic medical record (EMR)…
Abstract Number: 2256 • 2019 ACR/ARP Annual Meeting
Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
W. Benjamin Nowell¹, Elaine Karis ², Kelly Gavigan ¹, Laura Stradford ¹, Scott Stryker ³, Shilpa Venkatachalam ¹, Gregory Kricorian ³ and Jeffrey Curtis ⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is a frequently used therapy in both Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) due to its beneficial effects in both populations.…
Abstract Number: 369 • 2019 ACR/ARP Annual Meeting
Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review
Esteban Rubio¹, Alejandro Muñoz ¹ and Núria Casamira ², ¹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ²Medical Department, Gebro Pharma S.A., Barcelona, Spain
Background/Purpose: Methotrexate (MTX) is a commonly used drug for inflammatory joint diseases. Occasionally, its use has been associated with diffuse interstitial lung disease (DILD) development1. A…
Abstract Number: 2312 • 2019 ACR/ARP Annual Meeting
Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis: Results from Japanese Multi-institutional Study Using Research Electronic Data Capture
Suguru Honda¹, Ryoko Sakai ², Masako Majima ¹, Naoko Konda ¹, Hideto Takada ¹, Kazuhiko Yamamoto ³, Tsutomu Takeuchi ⁴ and Masayoshi Harigai ¹, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Riken Center for Integrative Medical Sciences, Kanagawa, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The risk of lymphoma is higher among patients with rheumatoid arthritis (RA) compared to general populations 1. Methotrexate (MTX), the anchor drug for RA,…
Abstract Number: 384 • 2019 ACR/ARP Annual Meeting
Prevalence and Predictors of Fibrosis in Rheumatological Patients on Therapy and Risk Factors for Chronic Liver Disease
Connie Lam ¹, Stephen Bloom ² and Alberta Hoi³, ¹School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia, ³School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia
Background/Purpose: The assessment of liver stiffness using liver elastography (Fibroscan) has facilitated early diagnosis of hepatic fibrosis in patients with chronic liver disease, but its…
Abstract Number: 2354 • 2019 ACR/ARP Annual Meeting
Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis
Helen Gosselt¹, Maxime Verhoeven ², Maurits de Rotte ³, Saskia Pluijm ⁴, Gerrit Jansen ⁵, Janneke Tekstra ², Sandra Heil ⁶, Floris Lafeber ², Mieke Hazes* ⁷ and Robert de Jonge* ⁸, ¹Amsterdam UMC, VU Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands and Erasmus MC, University Medical Center Rotterdam, Department of Clinical Chemistry, Rotterdam, The Netherlands, Amsterdam, Netherlands, ²UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ³Amsterdam UMC, Amsterdam Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Prinses Máxima Centre for Paediatric Oncology, Department of Paediatric Oncology Utrecht, The Netherlands, Utrecht, Netherlands, ⁵Amsterdam UMC, VU Medical Center, Amsterdam Rheumatology and immunology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁶Erasmus MC, University Medical Center Rotterdam, Department of Clinical Chemistry, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁷Erasmus MC, University Medical Center Rotterdam, Department of Rheumatology, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁸Amsterdam UMC, VU Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands, Amsterdam, Netherlands
Background/Purpose: Methotrexate (MTX) constitutes first-line therapy in rheumatoid arthritis (RA). However, up to 40% of RA patients do not benefit from MTX therapy. To restrain…
Abstract Number: 386 • 2019 ACR/ARP Annual Meeting
Idiopathic Granulomatous Mastitis: The Role of Rheumatologists in Treating This Rare Cause of Breast Pain
Sarah Ringsted¹ and Marcia Friedman ¹, ¹Oregon Health and Science University, Portland, OR
Background/Purpose: Idiopathic granulomatous mastitis (IGM) is an inflammatory breast disease occurring primarily in young to middle-aged women (1, 2). IGM typically presents with a tender,…
Abstract Number: 2357 • 2019 ACR/ARP Annual Meeting
Methotrexate Liver Toxicity in a Large Randomized Controlled Trial
Daniel Solomon¹, Nina Paynter ², Anna Rutherford ², Robert Glynn ³, Jean MacFadyen ⁴, Fengxin Lu ⁴, Chang Xu ⁴, Elizabeth Karlson ⁴ and Paul Ridker ², ¹Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Harvard Medical School - Boston, MA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Liver test abnormalities are known to predict liver pathology in patients using methotrexate (MTX). Monitoring guidelines for MTX suggest frequent assessment of liver tests…
Abstract Number: 505 • 2019 ACR/ARP Annual Meeting
Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission
Takeshi Suzuki¹, Marina Uchida ², Shoshi Shinagawa ², Machiko Mizushima ³, Takayasu Ando ³, Yutaka Gotou ³, Tomohiko Shibata ² and Kimito Kawahata ⁴, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Division of Rheumatology, Department of Internal Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ⁴Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: It has been recommended that tapering csDMARDs should be considered if a patient is in persistent remission. However, methods for tapering csDMARDs, including MTX,…
Abstract Number: 2363 • 2019 ACR/ARP Annual Meeting
Influence of the Clinical Characteristics and Different Genetic Polymorphisms Related to MTX, on the Efficacy and Safety in Patients with RA Treated with MTX in Monotherapy
Eugenio Chamizo Carmona¹, Carmen carrasco-Cubero ², Sara María Rojas Herrera ¹, María Eugenia Gonzalez Naranjo ², Juan José Aznar Sanchez ³, Raul Veroz Gonzalez ¹, Pedro Dorado ² and Adrian LLerena Ruiz ², ¹Hospital de Mérida, Mérida, Spain, ²CHU de Badajoz, Badajoz, Spain, ³Hospital de Mérida, Mérida
Background/Purpose: Rheumatoid arthritis (RA) produces joint destruction, functional deterioration, comorbidity and premature death. The best results are achieved with an early start of a treat-to-target…
Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Mark C. Genovese¹, Kenneth C. Kalunian², David Walker³, Jacques-Eric Gottenberg⁴, Kurt de Vlam⁵, Neelufar Mozaffarian⁶, Beatrix Bartok⁶, Franziska Matzkies⁶, Jie Gao⁶, Ying Guo⁶, Chantal Tasset⁷, John S. Sundy⁶ and Tsutomu Takeuchi⁸, ¹Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Northumbria Healthcare, United Kingdom, United Kingdom, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
Abstract Number: L11 • 2018 ACR/ARHP Annual Meeting
Etanercept and Methotrexate As Monotherapy or in Combination in Patients with Psoriatic Arthritis: A Phase 3, Double-Blind, Randomized Controlled Study
Philip J. Mease¹, Dafna D. Gladman², David H. Collier³, Christopher T. Ritchlin⁴, Philip S. Helliwell⁵, Lyrica Liu⁶, Gregory J. Kricorian³ and James B. Chung³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Toronto, Toronto, ON, Canada, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Rochester Medical Center, Rochester, NY, ⁵University of Leeds, Leeds, United Kingdom, ⁶Amgen Inc., South San Francisco, CA
Background/Purpose: Methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) such as etanercept (ETN) are often prescribed for psoriatic arthritis (PsA) either alone or in combination,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].